The role of pharmacotherapy in the treatment of chronic thromboembolic pulmonary hypertension (RCD code: II-1A.5)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2015, Vol 2, Issue 2
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a debilitating disease caused by chronic obstruction of major pulmonary arteries. The median age of patients at diagnosis of CTEPH is 63 years and both genders are equally affected. The symptoms are usually nonspecific, particularly in the early stages of the disease, which significantly delays the diagnosis. All patients with pulmonary hypertension (PH) of the unknown aetiology should be diagnosed for CTEPH, even without the information on pulmonary embolism in the medical history. Ventilation-perfusion scintigraphy of the lungs has the highest sensitivity in the diagnosis of CTEPH. A positive result of scintigraphy suggestive of CTEPH is not enough to diagnose the disease. Right heart catheterization and angiography of the pulmonary arteries definitively confirm the diagnosis. All patients with CTEPH should receive chronic oral anticoagulation using generally vitamin K antagonists (warfarin, acenocumarol). Pulmonary endarterectomy (PEA) is the only effective treatment for eliminating the cause of the disease. However, not all patients can be referred for pulmonary endarterectomy surgery. According to data from the European CTEPH Registry of the years 2007-2009, over 40% of patients is not subjected to the operation mainly due to the distal location of thromboembolic changes. Currently, riociguat is the only approved therapeutic agent for the pharmacological treatment of inoperable/persistent CTEPH. In some cases, Off-lebel use of drugs approved for PAH may be considered in symptomatic patients with inoperable CTEPH/persistent PH after PEA. Recent advances in balloon pulmonary angioplasty make it a promising therapeutic alternative for selected patients with non-operable CTEPH. JRCD 2015; 2 (2): 4–8
Authors and Affiliations
Barbara Widlińska, Grzegorz Kopeć, Piotr Podolec
Keywords
Related Articles
- EP ID EP245454
- DOI 10.20418/jrcd.vol2no2.164
- Views 89
- Downloads 0
Senning operation as a palliative therapy for a girl with complex heart defect and Eisenmenger syndrome (RCD code: II‑1A.4d)
Development of irreversible pulmonary hypertension in D-transposition of the great arteries (D-TGA) with ventricular septal defect (VSD) is a well-known phenomenon. Coexistence of left ventricular outflow tract obstructi...
Cardiopulmonary exercise tests in rare cardiovascular heart diseases
Cardiopulmonary exercise testing (CPET) is commonly used in clinica practice for both functional and diagnostic assessments of patients with cardiovascular and pulmonary disease. It provides assessment of the integrative...
A rare case of atypical mid‐variant takotsubo cardiomyopathy during dobutamine stress echocardiography
Dobutamine stress echo (DSE) allows for a relatively safe and accurate assessment of ischaemia in patients, who are unable to exercise. Side effects of DSE include nausea, vomiting, and in certain cases, excessive rise a...
55 years old patient with congenital heart malformation (RCD code: IV-1B.1a)
Cor triatriatum is a rare congenital anomaly where the left or right atrium is subdivided by a thin membrane, resulting in three atrial chambers. We present a case of 55 years old female who presented progressive dyspnea...
Cardiac involvement in eosinophilic granulomatosis with polyangitis (Churg Strauss) (RCD code: I-3A.7a)
Eosinophilic granulomatosis with polyangitis – EGPA (previously known as Churg‑Strauss syndrome) is a rare, systemic, necrotizing small‑vessel vasculitis with accompanying bronchial asthma, eosinophilia and eosinophilic...